Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.
暂无分享,去创建一个
Min Chen | Ming‐hui Zhao | W. Ju | V. Nair | M. Kretzler | R. Nelson | Jiancheng Wang | S. Eddy | H. Looker | Ming Xu | Lemin Zheng | F. Brosius | Liang Wu | Changjie Liu | D. Chang | Rui Zhan | Jinghua Sun | Shi-he Cui | E. Tanner | Ming-Hui Zhao | Emily Tanner
[1] C. Reutelingsperger,et al. Annexin A1 drives macrophage skewing to accelerate muscle regeneration through AMPK activation , 2020, The Journal of clinical investigation.
[2] Juan Cheng,et al. A Proresolving Peptide Nanotherapy for Site‐Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota , 2019, Advanced science.
[3] C. Thiemermann,et al. Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes , 2019, Front. Immunol..
[4] M. Cooper,et al. Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. , 2018, Journal of the American Society of Nephrology : JASN.
[5] F. Gavins,et al. Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury , 2018, International journal of molecular sciences.
[6] Choon-Sik Park,et al. Annexin A1 in plasma from patients with bronchial asthma: its association with lung function , 2018, BMC Pulmonary Medicine.
[7] N. Fountoulakis,et al. Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes , 2017, Diabetologia.
[8] Matthias Kretzler,et al. A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. , 2017, Kidney international.
[9] Mark E. Davis,et al. Store-Operated Ca2+ Channels in Mesangial Cells Inhibit Matrix Protein Expression. , 2015, Journal of the American Society of Nephrology : JASN.
[10] Y. Hung,et al. Urine Annexin A1 as an Index for Glomerular Injury in Patients , 2014, Disease markers.
[11] W. Wurst,et al. Highly Efficient Targeted Mutagenesis in Mice Using TALENs , 2013, Genetics.
[12] A. Nagy,et al. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production , 2013, Proceedings of the National Academy of Sciences.
[13] J. Navarro-González,et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.
[14] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[15] B. Rigas,et al. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. , 2010, Cancer research.
[16] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[17] M. Perretti,et al. Exploiting the Annexin A1 pathway for the development of novel anti‐inflammatory therapeutics , 2009, British journal of pharmacology.
[18] K. Sharma,et al. Transcription factors in the pathogenesis of diabetic nephropathy , 2009, Expert Reviews in Molecular Medicine.
[19] G. Wolf,et al. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. , 2008, Current diabetes reviews.
[20] C. Serhan,et al. Anti-inflammatory and proresolving lipid mediators. , 2008, Annual review of pathology.
[21] B. Croker,et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.
[22] Felix Eichinger,et al. Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.
[23] Nader Rifai,et al. Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.
[24] S. Feo,et al. Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthesis. , 2003, International immunopharmacology.
[25] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[26] M. Cooper,et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.
[27] R. Hannon,et al. Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration , 1996, Nature Medicine.
[28] G. J. Blackwell,et al. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation , 1979, Nature.
[29] A. Damazo,et al. Annexin 1 localisation in tissue eosinophils as detected by electron microscopy , 2013 .
[30] Kumar Sharma,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.